Sign in Subscribe
Drugs

Lung Cancer Treatment Advances: New Chemotherapy Options for Small Cell Lung Cancer

Strategic Insights

— 2 min read

Researchers in the Netherlands, Japan, and the United Kingdom have made significant advancements in the treatment of small cell lung cancer (SCLC). Their studies have explored the efficacy of third-line chemotherapy, weekly chemotherapy with paclitaxel and carboplatin, and the impact of platinum-based treatment on survival rates in elderly patients. These findings have important implications for the management of SCLC and the potential improvement of patient outcomes.

Key Takeaways:

  • Third-line chemotherapy for SCLC is still active in 1 in 4 patients, with a tumor response rate of 26% and a median survival time of 5 months (Lung Cancer, 2006;52(3):339-342).
  • Weekly chemotherapy with paclitaxel and carboplatin was well-tolerated and gave a high-response rate of 69% in patients with refractory or relapsed SCLC (Cancer Chemotherapy and Pharmacology, 2006;58(1):86-90).
  • Survival has improved in elderly patients with lung cancer treated by chemotherapy, with a significant increase in median survival and 1-year survival rates over the past 20 years (British Journal of Cancer, 2006;94(1):18-21).
  • Platinum-based treatment for SCLC has been established since 1995, and its use has been associated with improved survival rates in both the Netherlands and the UK.
  • Elderly patients with SCLC who received platinum combinations (Carboplatin or Cisplatin) had significantly improved survival compared to those who received single agents or other combinations (p < 0.05).

Statistics:

  • 18% of patients with SCLC received third-line chemotherapy in the Netherlands (Lung Cancer, 2006;52(3):339-342).
  • 29 patients were enrolled in the Japanese study evaluating weekly chemotherapy with paclitaxel and carboplatin (Cancer Chemotherapy and Pharmacology, 2006;58(1):86-90).
  • 322 elderly patients with SCLC received chemotherapy in the UK study (British Journal of Cancer, 2006;94(1):18-21).
  • The overall response rate for weekly chemotherapy with paclitaxel and carboplatin was 69% (95% CI: 52-86%) (Cancer Chemotherapy and Pharmacology, 2006;58(1):86-90).
  • The median survival time for SCLC patients treated with third-line chemotherapy was 5 months (range: 1-15 months) (Lung Cancer, 2006;52(3):339-342).

Sources:

  • Dejong, W.K., et al. (2006). Third-line chemotherapy for small cell lung cancer. Lung Cancer, 52(3), 339-342.
  • Mori, K., et al. (2006). Pilot phase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small-cell lung cancer. Cancer Chemotherapy and Pharmacology, 58(1), 86-90.
  • Yau, T., et al. (2006). Time and chemotherapy treatment trends in the treatment of elderly patients (age ≥ 70 years) with small cell lung cancer. British Journal of Cancer, 94(1), 18-21.

Read more